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Abstract
Purpose To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score
(GS) 8–10 disease treated with external beam radiotherapy (EBRT)+ androgen deprivation therapy (ADT) in the modern
era.
Methods Institutional databases of biopsy proven 641 patients with GS 8–10 PCa treated between 2000 and 2015 were
collected from 11 institutions. In this multi-institutional Turkish Radiation Oncology Group study, a standard database
sheet was sent to each institution for patient enrollment. The inclusion criteria were, T1–T3N0M0 disease according to
AJCC (American Joint Committee on Cancer) 2010 Staging System, no prior diagnosis of malignancy, at least 70Gy total
irradiation dose to prostate± seminal vesicles delivered with either three-dimensional conformal RT or intensity-modulated
RT and patients receiving ADT.
Results The median follow-up time was 5.9 years (range 0.4–18.2 years); 5-year overall survival (OS), biochemical
relapse-free survival (BRFS) and distant metastases-free survival (DMFS) rates were 88%, 78%, and 79%, respectively.
Higher RT doses (≥78Gy) and longer ADT duration (≥2 years) were significant predictors for improved DMFS, whereas
advanced stage was a negative prognosticator for DMFS in patients with GS 9–10.
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Conclusions Our results validated the fact that oncologic outcomes after radical EBRT significantly differ in men with
GS 8 versus those with GS 9–10 prostate cancer. We found that EBRT dose was important predictive factor regardless
of ADT period. Patients receiving ‘non-optimal treatment’ (RT doses <78Gy and ADT period <2 years) had the worst
treatment outcomes.
Keywords Pelvic radiotherapy · Grading system · Intensity modulated radiation therapy · Hormonal treatment ·
Androgen deprivation therapy
Behandlungsergebnisse vonmit definitiver Strahlentherapie behandelten Prostatakrebspatienten
mit einemGleason-Score von 8–10
TROD 09-001 Multizenterstudie
Zusammenfassung
Ziel Beurteilung der klinischen Ergebnisse und prognostischen Faktoren bei Patienten mit Prostatakrebs (PCa) mit Glea-
son-Score (GS) 8–10, die mit externer Strahlentherapie (EBRT) und einer Androgendeprivationstherapie (ADT) behandelt
wurden.
Methoden Zwischen 2000 und 2015 wurden insgesamt 641 mittels Biopsie diagnostizierte PCa-Patienten mit GS 8–10
von 11 Instituten in die Studie einbezogen. In dieser multizentrischen Studie der Turkish Radiation Oncology Group wurde
ein Standard-Datenbankformular zur Patientenaufnahme an jedes Zentrum geschickt. Die Einschlusskriterien waren: keine
vorherige Diagnose von Malignitäten, T1–T3 N0 M0 gemäß der TNM-Klassifikation des AJCC (American Joint Committee
on Cancer) von 2010 und eine RT von Prostata und Samenblasen mindestens bis 70Gy entweder mit dreidimensionaler
oder mit intensitätsmodulierter RT zusammen mit einer ADT.
Ergebnisse Die mediane Nachbeobachtungszeit betrug 5,9 Jahre (Spanne 0,4–18,2 Jahre). Das 5-Jahres-Gesamtüberleben
(OS), die biochemische Rezidivrate (BCR) und das fernmetastasenfreie Überleben (FÜ) der Patienten mit einer Nachbeob-
achtungszeit von 5 Jahren betrug jeweils 88%, 78% und 79%. Höhere Dosis der RT (≥78Gy) und langfristige ADT waren
signifikante Prädiktoren für ein verbessertes FÜ. Fortgeschrittenes Stadium bei Patienten mit GS 9–10 wurde als negativer
Prognosefaktor für das FÜ identifiziert.
Schlussfolgerung Unsere Ergebnisse zeigen, dass sich die onkologischen Ergebnisse zwischen GS 8 und GS 9–10 bei
Patienten mit PCa, die mit EBRT behandelt wurden, unterscheiden. Die EBRT-Dosis erwies sich als wichtiger prädiktiver
Faktor unabhängig von ADT. Patienten, die keine optimale Behandlung erhielten (RT mit Dosen <78Gy und ADT-Zeit
<2 Jahre), hatten die schlechtesten Behandlungsergebnisse.
Schlüsselwörter Beckenstrahlentherapie · Bewertungssystem · Intensitätsmodulierte Strahlentherapie · Hormonelle
Behandlung · Androgendeprivationstherapie
Introduction
The incidence of high-risk disease in prostate cancer pa-
tients, defined as clinical T3 disease, prostate specific anti-
gen (PSA) level >20ng/mL, or Gleason score (GS) 8–10, is
approximately 15% [1]. Although conflicting results have
been reported in previous series comparing different treat-
ment strategies, the treatment options in high-risk patients
include radical prostatectomy (RP), external beam radiation
therapy (EBRT) with androgen deprivation therapy (ADT),
and EBRT with a brachytherapy boost (EBRT+ BT) and
ADT in current practice [2–5].
GS is the most important predictive factor for outcome in
prostate cancer patients, and increasing evidence has sug-
gested that GS 8–10 disease defines a more aggressive natu-
ral history [6–9]. Although different risk classification sys-
tems stratified patients according to GS< 6, 7, and 8–10,
several reports indicated that this was not sufficient to pre-
dict prognosis [9–11]. However, high-risk prostate cancer
disease constitutes a heterogeneous group, including both
GS 8 and GS 9–10 disease [12]. The new International So-
ciety of Urological Pathology (ISUP) grading system iden-
tifies GS 9–10 as a different entity with worse outcomes
compared to GS 8 [8, 9]. Previous studies demonstrated
that patients with GS 9–10 disease had higher incidence
of biochemical failure and prostate-cancer specific mortal-
ity rates compared to patients with GS 8 disease after RP
[13, 14]. Thus, high-risk disease was divided into GS 8
and GS 9–10 in the new five-tiered prostate cancer grading
system (PCGS) [9].
A recent multi-institutional validation study for this new
PCGS was performed by including different multimodal
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therapeutic approaches [9, 13]. These studies evaluated the
efficacy of RP or EBRT+ BT in high-risk prostate cancer
patients [14, 15]. Additionally, some studies assessed the
outcomes of patients treated with EBRT and ADT [2, 4].
However, the studies assessing the efficacy of EBRT and
ADT have limited patient numbers with inadequate RT data
or ADT usage. Thus, these studies might inadvertently in-
clude biases against patients receiving EBRT by including
patients not receiving the current standard of care. Further-
more, previous retrospective studies comparing the efficacy
of RP and EBRT in high-risk prostate cancer included pa-
tients treated with lower EBRT doses or insufficient ADT
[16–18]. On the other hand, recent studies demonstrated
a clear benefit of dose escalation and long-term ADT on sur-
vival for patients with high-risk prostate cancer [16, 18–21].
Based on these findings, the aim of this study is to val-
idate the clinical outcomes in prostate cancer patients with
GS 8–10 disease treated with EBRT+ ADT in the modern
era. In addition, the prognostic factors effecting the survival
were analyzed in the entire cohort and in patients with GS 8
and GS 9–10 disease separately.
Materials andmethods
Patient selection
Clinical data of 641 biopsy proven patients with GS 8–10
prostate cancer treated between 2000 and 2015 were col-
lected from 11 institutions. In this multi-institutional Turk-
ish Radiation Oncology Group study, a standard database
sheet was sent to each institution for patient enrollment.
The inclusion criteria were T1–T3N0M0 disease accord-
ing to American Joint Committee on Cancer (AJCC) 2010
Staging System, no prior diagnosis of malignancy, at least
70Gy total irradiation dose to prostate± seminal vesicles
delivered with either three-dimensional conformal RT (3D-
CRT) or intensity-modulated RT (IMRT), and patients re-
ceiving ADT. Patients with clinical and radiological evi-
dence of lymph node metastasis or distant metastasis and
patients receiving hypofractionated RT were excluded from
the study. Additionally, patients treated for postoperative
adjuvant or salvage RT were also excluded.
Treatment protocol
All patients were treated according to their institutional
protocols; thus, the duration of ADT and RT treatment
fields and doses showed variations. The ADT consisted of
luteinizing hormone-releasing hormone analogue with or
without anti-androgen therapy. Neoadjuvant ADT was de-
livered in 596 patients (93.0%), and the median duration
was 3 months (range 1–12 months). Median duration of
total ADT time was 24 months (range 2–72 months).
All patients were treated with either 3D-CRT (288 pa-
tients, 44.9%) or IMRT (353 patients, 55.1%). The decision
of pelvic irradiation was based on institutional treatment
protocols. Local RT to the primary tumor and pelvic lym-
phatics was administered to 311 patients (48.5%), and 330
patients (51.5%) did not receive pelvic lymphatic irradia-
tion. The median RT dose to prostate± seminal vesicles was
75Gy (range 70–86Gy) and that of pelvic lymph nodes was
46Gy (range 40–62Gy).
Statistical analysis
All statistical analyses were performed using standard
software (SPSS version 21; SPSS Inc. [IBM], Chicago,
IL, USA). Biochemical failure was defined according to
Phoenix criteria (nadir PSA+ 2ng/dl) [22]. The primary
outcomes of interest were the overall survival (OS), bio-
chemical relapse-free survival (BRFS) and distant metas-
tasis-free survival (DMFS). Time to death or progression
was calculated as the period from the date of diagno-
sis to the date of death or the first clinical or imaging
evidence of disease recurrence. A chi-square (χ2) test or
Student’s t test was used to analyze the differences in
the clinical and pathological factors between patients with
GS 8 and GS 9–10 disease. The evaluated factors were,
age (<70 years vs. ≥70 years), PSA value at diagnosis
(10ng/mL vs. 10.1–19.9ng/mL vs. ≥20ng/mL), GS (8 vs.
9–10), clinical T stage (T2a–T2c vs. T3a–T3b), treatment
period, total RT dose (72Gy vs. 72–78Gy vs ≥78Gy),
RT technique (3D-CRT vs. IMRT), pelvic field irradia-
tion, duration of ADT (<2 years vs. ≥2 years). OS, BRFS,
and DMFS rates were estimated using the Kaplan–Meier
method. A univariate analysis was performed via the log-
rank test. Multivariate analyses were performed using the
Cox proportional hazards model, using covariates with a p
value of less than 0.05 based on the univariate analysis.
All p values of less than 0.05 were considered statistically
significant.
Results
Patient outcomes
The clinical characteristics of patients are presented in Ta-
ble 1. The median follow-up time was 5.9 years (range
0.4–18.2 years), and the median follow-up for alive patients
was 6.2 years (range 0.7–18.2 years), respectively. At the
final follow-up, 528 patients (82.4%) were alive, and 113
patients (17.6%) had died (51 [8.0%] of their disease; 62
[9.6%] of other causes). Of the 235 patients with relapse,
K
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Table 1 Patient and tumor characteristics for entire cohort, and patients with GS= 8 or GS= 9–10
Characteristics Entire cohort
(n= 641)
GS= 8
(n= 335)
GS= 9–10
(n= 306)
p
Age (years, median, range) 68 (41–88) 69 (41–88) 68 (51–87) 0.79
PSA (ng/mL, median, IQR) 21.3 (10.6–42.0) 22.1 (10.6–38.6) 20.0 (10.4–45.0) 0.34
Clinical stage
T2a 90 (14.6) 52 (15.5) 38 (12.4) 0.12
T2b 129 (20.1) 72 (21.5) 57 (18.6)
T2c 158 (24.6) 84 (25.1) 74 (24.2)
T3a 156 (24.3) 78 (23.3) 78 (25.5)
T3b 108 (16.8) 49 (14.6) 59 (19.3)
RT dose (Gy, median, range) 75.0 (70.0–86.0) 75.0 (70.0–86.0) 75.0 (70–86) 0.42
Primary RT dose
72Gy 110 (17.1) 55 (16.4) 55 (18.0) 0.19
72–78Gy 410 (64.0) 201 (60.0) 209 (68.3)
≥78Gy 121 (18.9) 79 (23.6) 42 (13.7)
RT technique
3D-CRT 288 (44.9) 140 (41.8) 148 (48.4) 0.16
IMRT 353 (55.1) 195 (58.2) 158 (51.6)
Treatment period
2000–2005 123 (19.2) 60 (17.9) 63 (20.6) 0.15
2006–2010 178 (27.8) 85 (25.4) 93 (30.4)
2011–2015 340 (53.0) 190 (56.7) 150 (49.0)
Pelvic field RT
Absent 330 (51.5) 182 (54.3) 148 (48.4) 0.13
Present 311 (48.5) 153 (45.7) 158 (51.6)
ADT time
<2 years 179 (27.9) 81 (24.2) 83 (27.1) 0.23
≥2 years 462 (72.1) 239 (75.8) 223 (72.9)
GS Gleason score, RT radiotherapy, Gy gray, 3D-CRT three dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy,
ADT androgen deprivation therapy, IQR interquartile range
Table 2 Recurrence patterns in entire cohort, and in patients with
GS 8 or GS 9–10 disease
Recurrence Entire co-
hort
n (%)
GS 8
n (%)
GS 9–10
n (%)
None 531 (82.8) 289 (86.3) 242 (79.1)
Local/locoregional 11 (1.7) 6 (1.8) 5 (1.6)
Distant metastasis 77 (12.0) 35 (10.4) 42 (13.7)
Local and distant
recurrence
22 (3.4) 5 (1.5) 17 (5.6)
GS Gleason score
110 patients (17.1%) had local, locoregional, or distant re-
lapse, 77 (12.0%) had distant metastases, 11 (1.7%) had
local or locoregional recurrences, and 22 (3.4%) had both.
The PSA relapse was observed in 60 patients (9.4%). The
distant metastasis rates were significantly higher in patients
with GS 9–10 compared to patients with GS 8 (19.3% vs.
11.9%; p= 0.02; Table 2).
Prognostic factors
The 5-year OS, BRFS and DMFS rates were 88%, 78%,
and 79%, respectively (Fig. 1). The tumor and patient char-
acteristics were similarly distributed in patients with GS 8
group and GS 9–10 group (Table 1).
The 5-year OS rate in patients with GS 8 was signifi-
cantly higher compared to patients with GS 9–10 (91% vs.
85%; p= 0.003; Fig. 2a). In univariate analysis, GS, AJCC
stage, EBRT doses, and pelvic nodal irradiation were sig-
nificant prognostic factors for OS (Table 3). In multivariate
analysis, older age, GS 9–10, advanced clinical stage and
low EBRT doses were significant negative predictors for
OS (Table 4).
The 5-year BRFS rate was significantly higher in patients
with GS 8 disease compared to that of GS 9–10 (82% vs.
73%; p= 0.002; Fig. 2b). The significant prognostic fac-
tors in univariate analysis were PSA value, GS, clinical
stage, and total RT dose. In multivariate analysis, higher
PSA value at diagnosis, GS 9–10, advanced clinical stage,
K
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Fig. 1 The 5-year overall survival (OS), biochemical relapse-free sur-
vival (BRFS), and distant metastases-free survival (DMFS) rates for
the whole cohort
Fig. 2 Compared to patients with GS 9–10 disease patients with GS 8
disease had significantly better 5-year overall survival (OS, 91% vs.
85%; p= 0.003; a), biochemical relapse-free survival (BRFS; 82% vs.
73%; p= 0.002; b), and distant metastases-free survival (DMFS) rates
(84% vs. 75%; p= 0.008; c). Blue line= GS 8 patient cohort, yellow
line= GS 9–10 patient cohort
K
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Table 3 Univariate analysis for overall survival (OS), biochemical relapse-free survival (BRFS), and distant metastasis-free survival (BRFS) for
entire cohort
Patient no OS BRFS DMFS
Covariate HR (95%CI) p HR (95%CI) p HR (95%CI) p
Age (years)
<70 344 1 0.09 1 0.93 1 0.86
≥70 297 1.38 (0.96–2.01) 0.99 (0.73–1.33) 0.97 (0.71–1.32)
PSA (ng/mL)
10 155 1 0.31 1 0.04 1 0.09
10.1–19.9 148 0.73 (0.45–1.20) 1.50 (0.94–2.40) 0.70 (0.46–1.06)
≥20 338 1.12 (0.72–1.73) 1.69 (1.13–2.54) 1.16 (0.81–1.66)
Gleason score
8 335 1 0.003 1 0.002 1 0.008
9–10 306 1.77 (1.21–2.59) 1.62 (1.20–2.20) 1.53 (1.12–2.09)
Clinical stage
T2a–T2c 377 1 0.003 1 0.002 1 <0.001
T3a–T3b 264 1.76 (1.21–2.54) 1.59 (1.18–2.14) 1.85 (1.36–2.52)
Treatment period
2000–2005 – 1 0.25 1 0.41 1 0.07
2006–2010 – 0.68 (0.40–1.16) 0.96 (0.65–1.43) 0.65 (0.42–1.01)
2010–2015 – 0.70 (0.43–1.14) 0.79 (0.54–1.15) 0.67 (0.48–0.90)
RT dose
72Gy 110 1 <0.001 1 <0.001 1 <0.001
72–78Gy 410 0.87 (0.49–1.54) 1.22 (0.75–1.99) 0.82 (0.51–1.32)
≥78Gy 121 0.40 (0.24–0.66) 0.61 (0.40–0.95) 0.43 (0.28–0.65)
RT technique
3D-CRT 288 1 0.59 1 0.91 1 0.58
IMRT 353 1.11 (0.76–1.64) 1.02 (0.75–1.38) 1.10 (0.80–1.50)
Pelvic field RT
Absent 330 1 0.003 1 0.09 1 0.008
Present 331 0.57 (0.39–0.83) 0.77 (0.56–1.04) 0.66 (0.48–0.90)
ADT duration
<2 years 179 1 0.80 1 0.22 1 0.82
≥2 years 462 0.80 (0.71–1.56) 0.82 (0.60–1.13) 1.04 (0.75–1.45)
GS Gleason score, RT radiotherapy, Gy gray, 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, ADT an-
drogen deprivation therapy, HR hazard ratio, PSA prostate-specific antigen
and lower total RT dose were negative predictors of BRFS
(Table 4).
The DMFS rate was also significantly higher in patients
with GS 8 disease, compared to patients with GS 9–10
(84% vs. 75%; p= 0.008; Fig. 2c). The significant prog-
nostic factors for DMFS in univariate analysis were GS,
clinical stage, total RT dose and pelvic lymphatic irradia-
tion. In multivariate analysis, GS 9–10, clinical T3a–T3b
disease, and 72Gy EBRT dose had negative impact on
DMFS.
Treatment outcomes of GS 8 and 9–10 disease
In univariate analysis, stage and total RT dose were signif-
icant predictors for OS, BRFS, and DMFS in patients with
GS 8 (Fig. 3). Additionally PSA level was predictor for OS
and DMFS, and ADT duration was significant prognostica-
tor for BRFS and DMFS. In multivariate analysis, advanced
stage and total RT dose ≥78Gy were significant prognostic
factors for OS, BRFS, and DMFS in GS 8. Moreover, PSA
>20ng/mL was significant predictor for OS and DMFS.
In patients with GS 9–10 disease, stage and total RT
dose were significant prognostic factors for OS and DMFS
in univariate analysis (Fig. 3). Another prognostic factor
for OS was pelvic lymphatic irradiation. ADT duration was
found to be significant factor for DMFS. However, we did
not find any significant impact of any factor on BRFS for
patients with GS 9–10 in univariate analysis. In multivariate
analysis, only advanced stage was a negative predictor for
OS in GS 9–10 disease. Higher total RT dose (≥78Gy) and
longer ADT duration (≥2 years) were significant predictors
for improved DMFS, whereas advanced stage was a neg-
K
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Table 4 Multivariate analysis for overall survival (OS), biochemical relapse-free survival (BRFS), and distant metastasis-free survival (BRFS) for
entire cohort
OS BRFS DMFS
Covariate HR (95%CI) p HR (95%CI) p HR (95%CI) p
Age (years) 1.04 (1.02–1.07) 0.002 1.01 (0.99–1.03) 0.36 1.01 (0.99–1.04) 0.21
PSA (ng/mL)
10 – – 1 0.02 – –
10.1–19.9 – – 1.66 (1.04–2.67) –
≥20 – – 1.71 (1.13–2.58) –
Gleason score
8 1 0.01 1 0.004 1 0.02
9–10 1.65 (1.12–2.44) 1.57 (1.16–2.14) 1.45 (1.05–1.99)
Clinical stage
T2a–T2c 1 0.01 1 0.02 1 0.001
T3a–T3b 1.64 (1.12–2.41) 1.43 (1.05–1.95) 1.70 (1.24–2.34)
RT dose
72Gy 1 0.003 1 0.02 1 0.001
72–78Gy 0.78 (0.44–1.39) 1.15 (0.70–1.90) 0.82 (0.51–1.33)
≥78Gy 0.45 (0.26–0.7) 0.60 (0.39–0.94) 0.47 (0.30–0.73)
Pelvic field RT
Absent 1 0.22 – – 1 0.54
Present 0.76 (0.50–1.16) – 0.90 (0.63–1.28)
PSA prostate-specific antigen, RT radiotherapy, HR hazard ratio, 95% CI 95% confidence interval
ative prognosticator for DMFS in patients with GS 9–10
disease.
Association of total radiotherapy dose with
outcomes
Patients receiving <78Gy had a significantly lower OS (HR:
0.45 [0.26–0.7]; p= 0.003), BRFS (HR: 0.60 [0.39–0.94];
p= 0.02), and DMFS (HR: 0.47 [0.30–0.73]; p= 0.001) than
those receiving ≥78Gy. Another subset analysis demon-
strated that patients receiving less than 78Gy radiotherapy
and ADT period less than 2 years had the worst OS, BRFS,
and DMFS rates (Table 5). Regardless of ADT period, pa-
tients receiving ≥78Gy had better outcomes compared to
patients receiving less than 78Gy.
Discussion
In this multi-institutional study, we found that GS 8–10
disease had worse outcomes, and should be subdivided
into GS 8 and GS 9–10 on the basis of differences in
OS, BRFS, and DMFS in prostate cancer patients treated
with definitive EBRT. Besides GS, advanced stage and low
EBRT doses were negative predictors of OS, BRFS, and
DMFS. Additionally, advanced age was predictor for OS
and higher PSA level at diagnosis was negative prognos-
ticator for DMFS. The distant metastasis was significantly
higher in GS 9–10 compared to GS 8 disease. Finally, we
found that total EBRT dose was important predictive factor
regardless of ADT period. Patients receiving ‘non-optimal
treatment’ (RT doses <78Gy and ADT period <2 years)
had the worst treatment outcomes.
Current risk stratification system includes GS 8–10 dis-
ease in high-risk group; however, several studies demon-
strated that oncological outcomes significantly differ in pa-
tients with GS 8 disease compared to those with GS 9–10
prostate cancer [7, 14, 23–27]. According to the current
classification systems, some patients with high-risk prostate
cancer fare quite well after local therapy, whereas others
succumb despite multimodal treatment. Therefore, in or-
der to better categorize high-risk prostate cancer patients,
a novel five-tiered Gleason grade group was defined, and
high-risk prostate cancer was further divided into group 4
(GS= 8) and group 5 (GS= 9–10) [11]. In this five-tiered
staging system, GS 8 and GS 9–10 are not grouped together
and 5-year BRFS after RP has been reported to be 48%, and
26% in a large cohort of patients with GS 8, and 9–10, re-
spectively [9]. Tsao et al. [7] also showed that GS 9–10 dis-
ease is associated with worse outcomes compared to GS 8
disease in a cohort of men with GS 8–10 prostate cancer.
In a validation study of new Gleason grading group con-
ducted with 358 patients treated with RP, Djaladat et al. [23]
demonstrated that GS 9–10 prostate cancer was associated
with BRFS and clinical recurrence-free survival. However,
no significant difference in OS was observed between GS 8
K
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Fig. 3 Univariate analysis for factors affecting overall survival (OS, a), biochemical relapse-free survival (BRFS, b) and distant metastases-free
survival (DMFS, c). GS Gleason score, RT radiotherapy, PSA prostate specific antigen, 3DCRT 3-dimensional conformal radiotherapy, IMRT in-
tensity modulated radiation therapy, ADT androgen deprivation therapy, Gy gray. *Factor is statistically significant
and GS 9–10 disease. Ham et al. [14] did also find that all-
cause mortality and prostate-cancer specific mortality rates
were significantly higher for patients with GS 9–10 prostate
cancer compared to those with GS 8 disease. In a popula-
tion-based validation study, Pompe et al. [24] found that
prostate-cancer-specific mortality rates in RP, BT, EBRT
and no local treatment arms different significantly among
new Gleason grade groups. In another study with 331,320
prostate cancer patients that underwent RT, RP, or other
treatments, He et al. [28] found that each Gleason grade
group increase approximately doubled the prostate-cancer-
specific mortality.
Besides these series conducted with RP or heterogeneous
treatment strategies, a few studies with EBRT also validated
K
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Table 5 Cox regression for overall survival, biochemical relapse-free survival, and distant metastasis-free survival according to radiotherapy doses
and androgen deprivation treatment period
RT dose, ADT period n (%) Hazard ratio (95% CI) p
Overall survival
<78Gy, <2 years 32 (5) 1 –
<78Gy, ≥2 years 367 (57) 0.56 (0.26–1.19) 0.13
≥78Gy, <2 years 148 (23) 0.30 (0.16–0.58) <0.001
≥78Gy, ≥2 years 95 (15) 0.30 (0.17–0.53) <0.001
Biochemical relapse-free survival
<78Gy, <2 years 32 (5) 1 –
<78Gy, ≥2 years 367 (57) 0.45 (0.22–0.90) 0.03
≥78Gy, <2 years 148 (23) 0.41 (0.24–0.69) 0.001
≥78Gy, ≥2 years 95 (15) 0.42 (0.24–0.76) 0.004
Distant metastasis-free survival
<78Gy, <2 years 32 (5) 1 –
<78Gy, ≥2 years 367 (57) 0.58 (0.30–1.13) 0.11
≥78Gy, <2 years 148 (23) 0.49 (0.28–0.86) 0.01
≥78Gy, ≥2 years 95 (15) 0.32 (0.19–0.54) <0.001
RT radiotherapy, Gy Gray, ADT androgen deprivation treatment
the new grading system [25–27]. Spratt et al. [26] ana-
lyzed 847 prostate cancer patients (95 patients with GS 8,
91 patients with GS 9–10 disease) treated with definitive
EBRT between 1990 and 2013, and the authors demon-
strated that higher Gleason grade, T stage and PSA levels
were independent predictors for worse BRFS, DMFS, and
prostate-cancer-specific survival. Berney et al. [27] found
that higher Gleason grade and extensive stage were sig-
nificant prognostic factors in 988 prostate cancer patients
treated with conservative treatment strategies. In another
‘National Cancer Database Study’ (NCDB), Yang et al.
[25] found that GS 9–10 disease derived less survival ben-
efit from ADT, in contrast to significant survival benefit
of ADT in GS 8 disease. In our study, we found that pa-
tients with GS 9–10 prostate cancer has significantly worse
OS, BRFS, and DMFS compared to patients with GS 8 dis-
ease. Our findings supported the validity of the new Gleason
grading system addressing high-risk disease should be sub-
divided into GS 8 and GS 9–10. Another tumor character-
istic negatively impairs survival was extensive tumor stage,
as it was previously demonstrated [26]. We also analyzed
GS 8 disease and GS 9–10 disease separately. We found that
extraprostatic disease and total EBRT dose ≥78Gy were
significant predictors for OS, BRFS, and DMFS, whereas
PSA value at diagnosis ≥20ng/mL was a negative prognos-
tic factor for OS and DMFS. Since distant metastasis was
significantly higher in GS 9–10 disease, extensive stage
was associated with worse DMFS, while higher RT doses
(≥78Gy) and longer ADT usage (≥2 years) was related with
better DMFS rates.
Emerging data have demonstrated a dose–response rela-
tionship for prostate cancer irradiation [29, 30]. Biochem-
ical failure, clinical failure, and distant metastasis were
all significantly lower and prostate-cancer-specific survival
significantly improved at 10 years after treatment with
78Gy as compared with 70Gy in patients with pretreatment
PSA >10ng/mL or high-risk disease [19]. In a comparative
effectiveness study of dose-escalated (≥75.6 to 90Gy) vs
standard-dose EBRT (from 68.4 to <75.6Gy) for prostate
cancer, Kalbasi et al. [16] demonstrated that dose-escalated
EBRT was associated with improved survival in the inter-
mediate-risk (HR, 0.84; 95%CI, 0.80–0.88; p< 0.001) and
high-risk groups (HR, 0.82; 95%CI, 0.78–0.85; p< 0.001)
but not for low-risk groups. The authors also stated a 7.8%
and 6.3% reduction in the hazard of death for intermediate-
and high-risk patients for every incremental increase of
about 2Gy in dose, respectively. In another NCDB study
with 20,279 prostate cancer patients, including 12,617at
intermediate risk and 7662at high risk, 71.3% received
EBRT alone and 28.7% received EBRT plus brachyther-
apy, Amini et al. [31] found that EBRT+ BT was associated
with improved survival compared to EBRT alone (75.6 to
81Gy; HR 0.75, p< 0.001). This significance remained
consistent for intermediate and high risk when analyzed
separately (HR 0.73 and 0.76, respectively, each p< 0.001).
The authors also concluded that EBRT+ BT or dose-es-
calated EBRT with doses of at least 79.2Gy should be
considered for intermediate- and high-risk prostate cancer.
Recently, Kishan et al. [2] demonstrated that treatment
with EBRT+ BT (median equivalent dose 91.5Gy) and
ADT was associated with better prostate-cancer-specific
mortality and longer time to DM compared to EBRT (me-
dian dose 73.4Gy) and ADT or RP in 1809 prostate cancer
patients with GS 9–10 disease. Similarly, our findings
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supported the benefit of higher RT doses on treatment
outcomes in GS 8–10 prostate cancer patients. Neither
ADT duration nor pelvic field irradiation was associated
with increased survival. Moreover, we demonstrated that
total doses of ≥78Gy was associated with better treatment
outcomes regardless to ADT duration.
The role of pelvic elective nodal irradiation in the man-
agement of prostate cancer is controversial. To date, ran-
domized studies have failed to demonstrate a survival ben-
efit with the addition of pelvic nodal irradiation in N0
prostate cancer patients. RTOG 9413 examined the role
of pelvic nodal irradiation in patients with ≥15% risk of
lymph node involvement based on the Roach formula [32].
Although initial results demonstrated a significant improve-
ment in PFS, favoring pelvic nodal irradiation updated re-
sults after a median follow-up of 6.6 years showed no sta-
tistically significant difference in either PFS or OS [33].
The French Genitourinary Study Group (GETUG)-01 study
evaluated survival in 446 patients with T1b–T3, N0pNx,
M0 prostate cancer who were randomly assigned to ei-
ther pelvic lymph node or prostate or prostate-only radi-
ation therapy. ‘High-risk’ group (T3 or Gleason score >6
or high PSA levels) received short-term 6-month neoadju-
vant and concomitant hormonal therapy. The results showed
that pelvic nodal irradiation did not statistically improve OS
in the whole population [34]. A post hoc subgroup analy-
sis showed a significant benefit of pelvic irradiation when
the risk of lymph node involvement was <15% according
to Roach formula. This benefit seemed to be limited to
patients who did not receive hormonal therapy. Blanchard
et al. evaluated the role of pelvic RT on the outcome in
high-risk (Gleason score ≥8, stage T3 or T4 disease, serum
PSA concentration >20ng/mL or pN+) localized prostate
cancer patients included in the GETUG 12 trial. Patients
were assigned to receive 3 years of ADT or ADT plus
4 cycles of chemotherapy. In their study 358 patients were
treated using primary RT and hormone therapy. There was
no difference in OS between groups. Although univariate
analysis showed worse BRFS with pelvic RT multivariate
analyses failed to show this benefit even when the analysis
was restricted to pN0 patients [35].
In the current study pelvic nodal irradiation did not af-
fect BRFS. These findings are consistent with the current
literature. However, the results of RTOG 0924 and the Euro-
pean PEACE 2 study will be important to make conclusions
about using pelvic nodal irradiation in the modern RT era.
Current standard of care for high-risk patients treated
with definitive RT is adding long-course ADT. Randomized
studies demonstrated the efficacy of RT and ADT especially
in high-risk patients, and at least 2–3 years of ADT was
found to be more effective than short-term ADT [20, 21,
36]. However, Yang et al. [25] demonstrated that patients
with GS 9–10 had smaller survival benefit from ADT com-
pared to patients with GS 8 disease. However, this NCDB
study provided only information on whether patients re-
ceived ADT, but the duration and type of hormone therapy
is not mentioned. Thus, still a subgroup of patients with
GS 9–10 may benefit from ADT. In the present study, we
could not identify any effect of ADT duration on survival,
which might be due to homogeneity of ADT in entire co-
hort. Since most of the patients (72%) received more than
2 years of ADT, our study may not have a power to detect
any possible effect of ADT duration.
This study possesses some limitations. First, it is a retro-
spective study that contains some biases in follow-up, treat-
ment selection, the duration of ADT and patient comorbidi-
ties. Second, no central pathology review was conducted,
and tertiary Gleason patterns were not routinely reported
over the study period. Finally, we evaluated the GS detected
from biopsy, not from prostatectomy specimens. However,
our study had a large number of patients with long follow-
up period, and a more homogeneous cohort treated with
EBRT and ADT in the modern era.
Conclusion
Although all patients with GS 8–10 are considered as hav-
ing high-risk prostate cancer, our results validated the fact
that oncologic outcomes after radical radiotherapy signifi-
cantly differ in men with GS 8 versus those with GS 9–10
prostate cancer. High-risk prostate cancer is biologically
a heterogeneous disease. Our results showed that GS 8
prostate cancer was associated with significantly improved
OS, BRFS, and DMFS compared to GS 9–10 disease. To-
gether with GS, clinical stage and total RT dose were other
important predictors for survival in patients with GS 8–10.
Since patients with GS 9–10 have higher rates of distant
metastasis compared to patients with GS 8, this group of
patient had better DMFS rates with higher RT dose and
longer ADT use. However, still more aggressive systemic
treatments may be required to achieve better outcomes. This
multi-institutional study validates the new five-tiered grad-
ing system classification for high-risk prostate cancer and
the fact that it can be used for patient counselling and de-
termining therapeutic strategies.
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